EA201190219A1 - Способы и композиции для лечения ишемических состояний и состояний, связанных с функцией митохондрий - Google Patents

Способы и композиции для лечения ишемических состояний и состояний, связанных с функцией митохондрий

Info

Publication number
EA201190219A1
EA201190219A1 EA201190219A EA201190219A EA201190219A1 EA 201190219 A1 EA201190219 A1 EA 201190219A1 EA 201190219 A EA201190219 A EA 201190219A EA 201190219 A EA201190219 A EA 201190219A EA 201190219 A1 EA201190219 A1 EA 201190219A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
compositions
mitochondrial
derivative
function
Prior art date
Application number
EA201190219A
Other languages
English (en)
Inventor
Франсиско Вильярреал
Пэм Р. Тауб
Алан С. Мэйсел
Джордж Ф. Шрайнер
Энн Мёрфи
Катрина Ямазаки
Гильермо Себальос
Original Assignee
Кардеро Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кардеро Терапьютикс, Инк. filed Critical Кардеро Терапьютикс, Инк.
Publication of EA201190219A1 publication Critical patent/EA201190219A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к композициям и способам профилактического и/или терапевтического лечения состояний, связанных с функцией митохондрий. В соответствии с различными аспектами настоящее изобретение включает введение одного или более соединений, выбранных из группы, состоящей из эпикатехина, производного эпикатехина, катехина, производного катехина, никорандила и производного никорандила, в количестве, эффективном для стимуляции функции митохондрий в клетках. Способы и композиции, описанные в настоящем документе, обеспечивают уменьшение объема инфаркта в сердце после постоянной ишемии или ишемического/реперфузионного (ИР) явления или способ замедления, облегчения или предотвращения неблагоприятного ремоделирования сердца и могут способствовать предотвращению нарушения митохондриального биогенеза и, таким образом, предотвращению последствий нарушения митохондриального биогенеза при различных заболеваниях и состояниях, а также обеспечивать активное лечение истощения митохондрий, которое, возможно, уже произошло.
EA201190219A 2009-04-17 2010-04-17 Способы и композиции для лечения ишемических состояний и состояний, связанных с функцией митохондрий EA201190219A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17055709P 2009-04-17 2009-04-17
US24350109P 2009-09-17 2009-09-17
PCT/US2010/031530 WO2010121232A1 (en) 2009-04-17 2010-04-17 Methods and compositions for treatment of ischemic conditions and conditions related to mitochondrial function

Publications (1)

Publication Number Publication Date
EA201190219A1 true EA201190219A1 (ru) 2013-01-30

Family

ID=42982894

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201190219A EA201190219A1 (ru) 2009-04-17 2010-04-17 Способы и композиции для лечения ишемических состояний и состояний, связанных с функцией митохондрий

Country Status (11)

Country Link
US (1) US20120095063A1 (ru)
EP (1) EP2418949A4 (ru)
JP (1) JP2012524077A (ru)
CN (1) CN102480951A (ru)
AU (1) AU2010236169A1 (ru)
BR (1) BRPI1014433A2 (ru)
CA (1) CA2759025A1 (ru)
EA (1) EA201190219A1 (ru)
MX (1) MX2011010939A (ru)
SG (1) SG175220A1 (ru)
WO (1) WO2010121232A1 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012170430A1 (en) * 2011-06-06 2012-12-13 Cardero Therapeutics, Inc. Methods and compositions for treatment of mitochondrial toxicity
WO2013022846A2 (en) * 2011-08-05 2013-02-14 Cardero Therapeutics, Inc. Flavonoid compounds
US20180193306A1 (en) 2012-03-23 2018-07-12 Cardero Therapeutics, Inc. Compounds and compositions for the treatment of muscular disorders and bone disorders
EP2827856A4 (en) * 2012-03-23 2016-03-09 Cardero Therapeutics Inc COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF MUSCLE DISEASES
EP2906197A1 (en) 2012-10-09 2015-08-19 The Procter & Gamble Company Method of identifying synergistic cosmetic combinations
EP2906946A1 (en) 2012-10-09 2015-08-19 The Procter & Gamble Company Method of identifying or evaluating beneficial actives and compositions containing the same
US20140179774A1 (en) * 2012-12-26 2014-06-26 Industrial Technology Research Institute Methods for inhibition of shc-1/p66 to combat aging-related diseases
CN110003159A (zh) * 2013-01-26 2019-07-12 斯法尔制药私人有限公司 合成儿茶素的新方法
US9138393B2 (en) 2013-02-08 2015-09-22 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin
US9144538B2 (en) 2013-02-08 2015-09-29 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin
JP6621400B2 (ja) * 2013-04-04 2019-12-18 スファエラ ファーマ プライベート リミテッド エピカテキン及び関連したポリフェノールの新規な類縁体
CN103316028A (zh) * 2013-07-17 2013-09-25 严建山 Polyflavanostilbene A在制备治疗或预防慢性心衰药物中的应用
CN106714770B (zh) 2014-07-23 2024-04-19 斯法尔制药私人有限公司 羟基类固醇化合物、其中间体、制备方法、组合物及其用途
CN105734151A (zh) * 2016-04-19 2016-07-06 张建 mtDNA拷贝数评估冠状动脉旁路移植术后新发房颤的应用
CN109415400A (zh) 2016-06-21 2019-03-01 斯法尔制药私人有限公司 (+)表儿茶素及其类似物的用途
WO2020172262A1 (en) * 2019-02-19 2020-08-27 James Janine Chromium composition and methods thereof
KR102191500B1 (ko) * 2020-03-30 2020-12-15 국립낙동강생물자원관 초석잠 추출물을 포함하는 기억력 및 인지기능 개선, 허혈 재관류 손상 예방 및 개선용 조성물
CN113024501B (zh) * 2021-03-30 2022-04-22 沈阳药科大学 具有抗甲型肝炎病毒活性的多甲氧基黄酮衍生物及其制备方法和用途
WO2024036223A1 (en) * 2022-08-10 2024-02-15 Epirium Bio Inc. Epicatechin inhibiting atp hydrolysis
CN115486415A (zh) * 2022-08-11 2022-12-20 中国农业大学 蜂帕金森模型的建立方法及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476241B1 (en) * 2000-09-05 2002-11-05 Mars Incorporated Synthesis of 4α-arylepicatechins
US7838552B2 (en) * 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
KR101473017B1 (ko) * 2006-07-05 2014-12-15 카오카부시키가이샤 노화 억제제
AU2007275561B2 (en) * 2006-07-21 2013-12-19 Mars, Incorporated Improvement of arginase levels/activity
US8648059B2 (en) * 2008-03-13 2014-02-11 The Regents Of The University Of California Use of epicatechin and derivatives and salts thereof for cardiac protection of ischemic myocardium and to ameliorate adverse cardiac remodeling

Also Published As

Publication number Publication date
AU2010236169A1 (en) 2011-11-10
EP2418949A1 (en) 2012-02-22
US20120095063A1 (en) 2012-04-19
MX2011010939A (es) 2012-01-20
EP2418949A4 (en) 2012-11-28
BRPI1014433A2 (pt) 2015-08-25
CN102480951A (zh) 2012-05-30
CA2759025A1 (en) 2010-10-21
SG175220A1 (en) 2011-12-29
WO2010121232A1 (en) 2010-10-21
JP2012524077A (ja) 2012-10-11

Similar Documents

Publication Publication Date Title
EA201190219A1 (ru) Способы и композиции для лечения ишемических состояний и состояний, связанных с функцией митохондрий
WO2013022846A3 (en) Flavonoid compounds
PH12017502425A1 (en) Benzoxazepin oxazolidinone compounds and methods of use
EA201591610A1 (ru) Ингибиторы кинуренинового пути
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
EA201391720A1 (ru) Замещенные диоксопиперидинилфталимидные производные
EA201592182A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201490396A1 (ru) Ингибиторы репликации вирусов гриппа
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
AR088195A1 (es) Composiciones farmaceuticas de n-metil-2-[3-(e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]-benzamida
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
EA201301154A1 (ru) Разветвленные производные 3-фенилпропионовой кислоты и их применение
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
EA201490254A1 (ru) Комбинированное лечение гепатита с
WO2012072713A3 (en) Lysine demethylase inhibitors such as cyclylcyclopropanamine derivatives for use in the treatment of diseases and disorders associated with flaviviridae
EA201390198A1 (ru) Гетероциклическое соединение
EA201492290A1 (ru) Составы и способы для вагинальной доставки антипрогестинов
WO2014141110A3 (en) Aminonitriles as kynurenine pathway inhibitors
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
WO2012080497A3 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
EA201400067A1 (ru) Новая терапевтическая композиция, содержащая апоморфин в качестве активного ингредиента
EA201891261A1 (ru) Фармацевтическая композиция, содержащая производные глутаримидов, их применение для лечения эозинофильных заболеваний